Year: 2011
Type: review
Abstract: Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.
Source: Human Vaccines
DOI: 10.4161/hv.7.3.14266
Authors: Kevin J. Whaley, Andrew Hiatt, Larry Zeitlin
Institution: Mapp Biopharmaceutical (United States)
Language: English
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: bronze
Awards: G1081238962, Monoclonal Antibodies in Biodefense: Ebola Viruses, A HUMAN MONOCLONAL COCKTAIL FOR RSV IMMUNOTHERAPY, G3616330111, Plant-Made Microbicides and Mucosal Vaccines for STIs, G5028759665, MONOCLONAL ANTIBODIES FOR ALZHEIMER'S IMMUNOTHERAPY, Monoclonal Antibodies for Alzheimer's Immunotherapy, G7110435581
OpenAlex ID: W2065804181